Legal
Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates during a partnership that spanned seven years.
A disappointed Merck said it was reviewing its options for a possible appeal, while a pleased Gilead said if an appeal came, it was confident a higher court would come to the same verdict as the federal appeals court.
Reynolds claimed that his company’s product, called NeuroRelease, could essentially end paralysis.
The plaintiffs in the case alleged that Forest intentionally attempted to delay and impair generic competition of its immediate-release formulation of Namenda.
The U.S. Department of Justice said the two charitable organizations, Good Days and Patient Access Network Foundation, allowed seven pharmaceutical companies to funnel money through their organization to provide Medicare patients with assistance in paying for medications developed by those companies.
Centrient Pharmaceuticals (“Centrient”), the global leader in the production and commercialisation of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has
As an historic lawsuit over opioids was to enter court today, four key defendants reached a settlement.
Netherlands-based Pharming Group NV has denied any involvement in a potential theft of intellectual property belonging to CSL Behring from Joseph Chiao, who recently joined Pharming as medical director.
Citing “sources familiar with the matter,” The Wall Street Journal reported that the agreement, should it be reached, would ultimately settle the matter for the company related to sales of Duragesic and Nucynta.
PRESS RELEASES